Source Fact: IBK Investment & Securities / June 26, 2026
Investment Opinion & Target Price: Not Rated / Current Price (as of June 25): 52,300 KRW
Core Momentum: Target timeline for submitting the official IND for its proprietary DAC pipeline (ORM-1153) within the year and capturing premium valuation tailwinds from competitive Big Pharma licensing races
📊 1. [Section Title: Valuation and Investment Metrics Analysis]
- Rating & Target Price: This analysis is released as a ‘Not Rated’ corporate report with no official target price specified. The current stock price stands at 52,300 KRW, with market capitalization tracked at 1,136 billion KRW.
- Historical Financial Overview:
- Revenue: Jumped sharply from 0 KRW in 2021 to 135 billion KRW in 2023 following core licensing milestones, tapering to 21 billion KRW in 2024 and 0 KRW in 2025.
- Operating Profit: Recorded a milestone surplus of 98 billion KRW in 2023, shifting back to a deficit of -10 billion KRW in 2024 and -55 billion KRW in 2025.
- Net Income: Logged a profit of 70 billion KRW in 2023, turning to a deficit of -7 billion KRW in 2024 and -46 billion KRW in 2025.
- Per-Share Metrics & Valuation Multiples (As of 2025):
- EPS (Earnings Per Share): Reported at -378 KRW for 2024 and -2,206 KRW for 2025.
- PER (Price-to-Earnings Ratio): Tracked at -54.4x.
- PBR (Price-to-Book Ratio): Logged at 21.3x.
- EV/EBITDA: Tracked at -44.0x.
- ROE (Return on Equity): Logged at -39.3%.
🚀 2. [Section Title: Target Addressable Market (TAM) & Detailed Earnings Estimates]
- Differentiated DAC Platform Advantage:
- Owns a proprietary full-stack platform for Degrader-Antibody Conjugates (DAC), combining targeted delivery capabilities of antibodies with Targeted Protein Degrader (TPD) payloads.
- Successfully out-licensed its leukemia candidate ORM-6151 to global pharmaceutical leader BMS in October 2023 in a deal valued at approximately 243.5 billion KRW.
- Validated its technological edge further in July 2024 by securing a secondary platform out-licensing contract with Vertex for its TPD² technology.
- Proprietary Hematological Pipeline (ORM-1153) Pipeline status:
- ORM-1153, a CD123-targeting DAC incorporating a GSPT1 payload, is currently leading internal development pipelines.
- Preclinical trials demonstrated consistent anti-cancer efficacy across multiple genetic mutations, with an internal goal to submit an Investigational New Drug (IND) application within the year.
- Developed to target hematological malignancies including Acute Myeloid Leukemia (AML)—a high unmet-need condition with recurrence rates exceeding 50%—making its impending clinical entry a prime catalyst for pipeline valuation expansion.
- Global Big Pharma M&A Momentum:
- Global pharmaceutical giants are actively engaging in platform land-grabs, evidenced by Roche’s co-development contract with C4 Therapeutics and J&J’s $1.0 billion acquisition of Firefly Bio.
- The collection of Phase 1 clinical data for ORM-6151 in AML/MDS patients, slated for 1H27, is anticipated to serve as the definitive real-world verification point for Orum’s DAC platform value.
📝 Editor’s Comment (by K-STOCK Editor)
Orum Therapeutics’ specialized DAC platform technology and its track record of securing high-profile out-licensing deals with heavyweights like BMS and Vertex provide clear evidence of its technical competitive edge in the global market. Furthermore, the aggressive multi-million dollar positioning and acquisition wave among global Big Pharma players validate the underlying value of early-stage platform consolidation. However, market participants must critically analyze the structural financial volatility typical of research-heavy biotech firms, where a massive revenue spike from an out-licensing milestone (2023) is quickly followed by a return to operational deficits as clinical development costs build back up (2025). Substantial time horizons and classic binary clinical risks remain before the company achieves its year-end target for the ORM-1153 IND filing or delivers its highly anticipated Phase 1 data in 1H27. Rather than building a thesis entirely on market hype, a balanced and careful approach that systematically tracks real clinical progression and data readouts is highly recommended.
📢 Disclaimer & Source Information Source: This content has been newly structured and written based on official financial facts and quantitative data extracted from publicly disclosed securities reports
Investment Risk Warning: This material is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, nor should it be interpreted as a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact us at ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
